Steven Hung-Yi Fan

Plain English
This study focused on improving a technique called adenine base editing, which can change specific DNA sequences to potentially correct genetic mutations. Researchers tested this technique using a large number of guides in cell lines and live mice, finding strong consistency in the results, with correlation scores between 0.83 and 0.92. They developed a new predictive tool called BEDICT2.0, which accurately forecasts the editing efficiency of this technique, showing potential for correcting many harmful genetic mutations. Who this helps: This benefits patients with genetic disorders and researchers working on gene therapies.

Plain English
This study looked at using a new gene-editing technique called prime editing to treat a liver disease in mice. Researchers found that they could successfully edit genes in liver cells, achieving a correction rate of up to 20.7% for a specific mutation linked to phenylketonuria, which lowered harmful blood levels of a substance called L-phenylalanine from over 1,500 to below the safe threshold of 360. This is important because it shows a promising method for treating not only phenylketonuria but also other genetic liver diseases, potentially paving the way for future use in humans. Who this helps: This benefits patients with genetic liver diseases and their doctors.

Plain English
Researchers studied two types of experimental vaccines for the Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV), which has no approved vaccine and can be deadly. They found that all vaccine approaches they tested protected mice from SFTSV infection and generated strong, long-lasting immune responses. The mRNA vaccine showed slightly stronger antibody responses, while a combination of vaccines provided a better cellular immune response. Who this helps: This research benefits vaccine developers and potentially patients at risk for SFTSV.

Plain English
This study focused on creating a new type of flu vaccine using mRNA technology to protect against a specific strain of bird flu called H5 clade 2.3.4.4b, which is spreading rapidly among birds and poses a threat to humans. The researchers found that their mRNA vaccine triggered strong immune responses in lab mice and male ferrets, producing effective antibodies that could protect against the virus. This is important because it shows that mRNA vaccines can be a fast and efficient way to respond to potential flu pandemics. Who this helps: This benefits patients and public health officials by providing a new option for flu prevention during outbreaks.

Plain English
This study looked at a new type of flu vaccine made with nucleoside-modified mRNA, which could be better than traditional flu vaccines that are made using chicken eggs. Researchers found that mice given the mRNA vaccine produced stronger immune responses against the H3N2 virus compared to those given the standard egg-based vaccine. Specifically, the mRNA vaccine helped protect the mice from infection more effectively because it avoided issues related to how vaccines are adapted during production in eggs. Who this helps: This helps patients, especially those at risk for flu complications, by potentially providing more effective vaccines.

Plain English
Researchers created a new mRNA vaccine to protect against a dangerous strain of bird flu known as H5 clade 2.3.4.4b. They found that this vaccine triggered a strong immune response in mice and ferrets and effectively prevented illness and death in ferrets exposed to the virus. This study is important because it shows potential for developing effective vaccines against bird flu, which could pose a risk to human health. Who this helps: This helps patients and public health officials in preparing for possible future outbreaks of bird flu.

Plain English
Researchers developed a new type of flu vaccine using messenger RNA (mRNA) that targets all 20 known subtypes of influenza viruses. When tested on mice and ferrets, the vaccine produced strong immune responses and protected them from various strains of the virus, showing that it can be effective against different flu types. This is important because it could lead to better preparedness for future flu pandemics, making vaccines more effective when new virus strains emerge. Who this helps: This helps patients at risk of severe flu infections, including those with weakened immune systems.

Plain English
This study looked at a rare disease called mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) and tested a new gene-editing method in mice. The researchers successfully used a technique called CRISPR/Cas9 to insert a working version of a gene responsible for a key enzyme, resulting in a long-term reduction of harmful substances in the bloodstream. Specifically, the treated mice maintained lower levels of nucleosides for a year, indicating the gene editing was effective and produced a significant increase in the enzyme's activity. Who this helps: This research benefits patients with MNGIE and their doctors by providing a potential new treatment for this challenging condition.

Plain English
Researchers used a gene-editing tool called CRISPR to permanently disable a gene in monkeys' livers that controls cholesterol production, delivering it through tiny fat particles injected into the bloodstream. After a single injection, the monkeys' cholesterol dropped by about 60% and stayed low for at least 8 months without any additional treatment. This proves that gene editing could offer heart disease patients a one-time treatment instead of taking cholesterol drugs for life.

Plain English
Researchers studied how different types of COVID-19 vaccines (mRNA vaccines versus a protein-based vaccine) affect the immune system's ability to fight SARS-CoV-2. They found that a single dose of the mRNA vaccine triggered strong immune responses, leading to the production of specific immune cells and neutralizing antibodies, while the protein vaccine did not produce the same effect. This is important because robust immune responses can offer better protection against COVID-19. Who this helps: This helps patients by providing better vaccine options for stronger immunity against COVID-19.

Plain English
This study looked at a protein called NHE5, found primarily in brain cells, and its role in managing the recycling of certain receptors that help cells communicate and move. Researchers discovered that when they reduced NHE5, it hurt the cells' ability to recycle a receptor called MET, leading to less cell movement and disorientation; specifically, this reduction raised the pH in certain cell compartments and disrupted signaling pathways. These findings matter because they provide insights into how cells communicate and move, which could affect how we understand brain tumors and other conditions related to cell behavior. Who this helps: This helps researchers studying cancer and cell migration, particularly in brain tumors.